Shots:
- Tesaro (GSK’s subsidiary) has entered into an exclusive license agreement to use Alteogen’s ALT-B4 for the development & commercialization of a SC formulation of dostarlimab
- As per the deal, Alteogen will be responsible for clinical and commercial supply of ALT-B4 to Tesaro, in exchange for $20M upfront & ~$265M in development, regulatory & sales milestones, with royalties on the sales
- ALT-B4 is a recombinant human hyaluronidase developed with Hybrozyme tech that temporarily hydrolyzes hyaluronan in the extracellular matrix, enabling large-volume SC delivery of drugs typically administered by IV infusion
Ref: PRnewswire | Image: Tesaro & Alteogen |Press Release
Related News: AstraZeneca Secures China Rights to AbelZeta’s GPC3 Armored CAR-T Therapy for Solid Tumor
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
